EA201300103A1 - Способ получения хинолин-3-карбоксамидов - Google Patents

Способ получения хинолин-3-карбоксамидов

Info

Publication number
EA201300103A1
EA201300103A1 EA201300103A EA201300103A EA201300103A1 EA 201300103 A1 EA201300103 A1 EA 201300103A1 EA 201300103 A EA201300103 A EA 201300103A EA 201300103 A EA201300103 A EA 201300103A EA 201300103 A1 EA201300103 A1 EA 201300103A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mixture
spcob
carboxamidide
quinoline
receiving
Prior art date
Application number
EA201300103A
Other languages
English (en)
Other versions
EA021171B1 (ru
Inventor
Лиллемор Мария Бок
Пер Хеннинг Хольмберг
Карл-Эрик Янссон
Original Assignee
Эктив Байотек Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эктив Байотек Аб filed Critical Эктив Байотек Аб
Publication of EA201300103A1 publication Critical patent/EA201300103A1/ru
Publication of EA021171B1 publication Critical patent/EA021171B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описывается способ получения соединения формулы (I) путем реакции соответствующего алкилового сложного эфира и производного анилина в кипящей смеси, содержащей алифатический растворитель или смесь алифатических растворителей, имеющих температуру кипения в интервале 68-191°С; конденсации паров кипящей смеси; обработки конденсированных паров поглотителем спирта или смесью поглотителей спирта и возвращения конденсированных паров обратно в реакционную смесь.
EA201300103A 2010-07-09 2011-07-07 Способ получения хинолин-3-карбоксамидов EA021171B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36284910P 2010-07-09 2010-07-09
EP10169162 2010-07-09
PCT/EP2011/061490 WO2012004338A1 (en) 2010-07-09 2011-07-07 Method for manufacturing of quinoline-3-carboxamides

Publications (2)

Publication Number Publication Date
EA201300103A1 true EA201300103A1 (ru) 2013-06-28
EA021171B1 EA021171B1 (ru) 2015-04-30

Family

ID=43348982

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300103A EA021171B1 (ru) 2010-07-09 2011-07-07 Способ получения хинолин-3-карбоксамидов

Country Status (21)

Country Link
US (1) US8871936B2 (ru)
EP (1) EP2590949B1 (ru)
JP (1) JP5881691B2 (ru)
KR (1) KR101855195B1 (ru)
CN (1) CN103119023B (ru)
AU (1) AU2011275720B2 (ru)
BR (1) BR112012033465A2 (ru)
CA (1) CA2802006C (ru)
DK (1) DK2590949T5 (ru)
EA (1) EA021171B1 (ru)
ES (1) ES2563208T3 (ru)
HK (1) HK1183864A1 (ru)
IL (1) IL223583A (ru)
MX (1) MX2013000288A (ru)
NZ (1) NZ604176A (ru)
PL (1) PL2590949T3 (ru)
PT (1) PT2590949E (ru)
SG (1) SG186430A1 (ru)
UA (1) UA108381C2 (ru)
WO (1) WO2012004338A1 (ru)
ZA (1) ZA201209370B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
CN108358842A (zh) * 2014-08-28 2018-08-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
KR102533033B1 (ko) 2014-09-23 2023-05-15 액티브 바이오테크 에이비 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
MX2017006110A (es) 2014-11-19 2017-07-27 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
KR101807124B1 (ko) * 2015-12-02 2017-12-07 현대자동차 주식회사 연료전지차량의 비상 운전 제어 방법
KR20220149579A (ko) 2020-03-03 2022-11-08 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
CN116782902A (zh) 2020-07-23 2023-09-19 伊拉兹马斯大学鹿特丹医学中心 作为骨髓增殖性肿瘤中的新治疗靶标的s100蛋白
JP2024503372A (ja) 2021-01-18 2024-01-25 アクティブ バイオテック エイビー 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩
US20240285532A1 (en) 2021-05-25 2024-08-29 Active Biotech Ab A plurality of tasquinimod particles and use thereof
IL309486A (en) 2021-07-02 2024-02-01 Active Biotech Ab A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product
KR20230149402A (ko) 2022-04-20 2023-10-27 목포대학교산학협력단 판막 석회화 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868379A (en) * 1972-04-28 1975-02-25 Warner Lambert Co Heterocyclic amides of 4-hydroxy-2H-1-benzothiopyran-3-carboxylic acid 1,1-dioxide
US3769292A (en) * 1972-04-28 1973-10-30 Warner Lambert Co N-(pyridyl)2h 1-benzothiopyran-3-carboxamide-4-hydroxy 1,1-dioxides
AT345847B (de) * 1974-11-08 1978-10-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer 4-hydroxy-2h- naphtho- (2,1-e)-1,2-thiazin-3-carboxamid-1,1-dioxid und deren salze
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US8022215B2 (en) * 2008-02-15 2011-09-20 Merck Sharp & Dohme Corp. Fused pyridone M1 receptor positive allosteric modulators
PL2276740T3 (pl) * 2008-04-28 2015-01-30 Actavis Group Ptc Ehf Ulepszony sposób wytwarzania pochodnych chinolino-3-karboksyamidowych

Also Published As

Publication number Publication date
UA108381C2 (uk) 2015-04-27
EA021171B1 (ru) 2015-04-30
ES2563208T3 (es) 2016-03-11
HK1183864A1 (zh) 2014-01-10
EP2590949B1 (en) 2015-11-25
JP5881691B2 (ja) 2016-03-09
MX2013000288A (es) 2013-05-22
CA2802006A1 (en) 2012-01-12
US20130109860A1 (en) 2013-05-02
CN103119023B (zh) 2014-12-24
ZA201209370B (en) 2014-03-26
EP2590949A1 (en) 2013-05-15
AU2011275720A1 (en) 2013-01-10
AU2011275720B2 (en) 2015-05-14
PT2590949E (pt) 2016-03-07
DK2590949T3 (en) 2016-02-29
US8871936B2 (en) 2014-10-28
JP2013529672A (ja) 2013-07-22
SG186430A1 (en) 2013-01-30
WO2012004338A1 (en) 2012-01-12
CA2802006C (en) 2018-09-25
KR101855195B1 (ko) 2018-05-08
IL223583A (en) 2016-03-31
NZ604176A (en) 2014-10-31
PL2590949T3 (pl) 2016-06-30
DK2590949T5 (en) 2016-05-23
KR20130091730A (ko) 2013-08-19
CN103119023A (zh) 2013-05-22
BR112012033465A2 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
EA201300103A1 (ru) Способ получения хинолин-3-карбоксамидов
AR091651A1 (es) Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
CU24341B1 (es) Compuestos y composiciones orgánicas inhibidores del ácido graso sintetasa (fasn) útiles para el tratamiento del cáncer, infecciones virales, obesidad y diabetes
EA201490831A1 (ru) Способ получения хинолиновых производных
EA201391637A1 (ru) Ингибиторы вируса гепатита c
EA201391522A1 (ru) Способ получения соединений для применения в качестве ингибиторов sglt2
RU2015102761A (ru) Водная композиция с алканоламином и способ удаления кислых газов из газовых смесей
AR117002A2 (es) Proceso para la preparación de inhibidores de quinasa c-fms
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
MA32721B1 (fr) Composition pharmaceutique solide
EA201590770A1 (ru) Ингибиторы вируса гепатита с
EA201490998A1 (ru) Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)-уксусной кислоты
WO2012099736A3 (en) Improved process for preparation of high molecular weight molybdenum succinimide complexes
ES2571043T3 (es) Preparación de dihidropiridinas
IN2014MN00976A (ru)
BR112013023786A2 (pt) processo para a preparação de derivados de s-triazina
EA201490383A1 (ru) Способ получения ситаглиптина и его фармацевтически приемлемых солей
IN2013MN02407A (ru)
MY182218A (en) Integrated process for the preparation of compounds useful as fuel components
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью
CO6680619A2 (es) Formulaciones
BR112013011244A2 (pt) processo para a preparação de derivados e ácido 3-(6-amino-piridin-3il)-2-acrílico
MX349740B (es) Proceso para la preparacion de fenilpropanonas sustituidas.
EA201290681A1 (ru) Синтетическое промежуточное соединение производного оксазола и способ его получения
RU2016101945A (ru) Способ получения соединений алкоксида индия, соединения алкоксида индия, получаемые согласно способу, и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU